Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Traws Pharma, Inc. (NASDAQ: TRAW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Traws’ clinical-stage antiviral programs, financial position, governance and executive compensation, and they complement the company’s press releases.
Through periodic reports such as the Form 10-K and proxy statements, Traws describes its business focus on developing investigational oral small molecule antivirals for respiratory viral diseases, including COVID-19, Long COVID, bird flu and seasonal influenza. The definitive proxy statement (DEF 14A) outlines board structure, incentive compensation plans and matters submitted to stockholders, while also providing context on corporate governance and director elections.
Current reports on Form 8-K, several of which are referenced in the provided data, document material events such as interim clinical data announcements for ratutrelvir, approval to proceed with Phase 2 COVID-19 studies, dosing of the first Phase 2 subjects, quarterly earnings releases, option and restricted stock unit grants to executives, and the appointment of new board members and officers. These filings also confirm that Traws’ common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
Investors and analysts can use this page to review how Traws reports on its clinical progress with ratutrelvir and tivoxavir marboxil, its legacy oncology programs rigosertib and narazaciclib, and its financial results and capital structure. Forms related to executive and director compensation, incentive plans and governance changes provide additional insight into how the company aligns management incentives with its development priorities.
Stock Titan enhances access to these filings by organizing them chronologically and by form type, and by offering AI-powered summaries that explain the key points of lengthy documents such as annual reports, quarterly updates and 8-Ks. This allows users to quickly understand the significance of new filings, track trends in Traws’ disclosures and identify items such as clinical milestones, financing arrangements or changes in leadership that may be important for evaluating TRAW stock.
Traws Pharma (TRAW) furnished an update on November 13, 2025 announcing it issued a press release with financial results for the quarter ended September 30, 2025 and began using a new corporate presentation. Both materials were provided as Exhibits 99.1 and 99.2.
The materials under Item 7.01 are being furnished, not filed, which means they are not subject to Section 18 liability and are not incorporated into other filings unless specifically referenced. The company also included standard forward-looking statements language.
Traws Pharma (TRAW) reported executive equity grants. On October 12, 2025, the board’s Compensation Committee approved stock options for five executives at an exercise price of $3.01 per share, each with a 10‑year term and one‑year cliff vesting (vesting in full on the first anniversary, subject to continued service). Grants include 64,839 options to the CEO, and 32,406 each to the CFO, Chief Science Officer (Virology), and Chief Medical Officer, plus 22,435 to the COO. Awards were made under the Amended and Restated 2021 Incentive Compensation Plan.
Traws Pharma (TRAW) reported an insider equity award. Chief Science Officer, Virology, Charles David Pauza acquired 32,406 stock options at an exercise price of $3.01 on 10/12/2025, as disclosed on Form 4.
The options vest 100% on 10/12/2026 and expire on 10/12/2035. Following the transaction, the reporting person beneficially owns 32,406 derivative securities directly. This reflects routine equity compensation.
Traws Pharma (TRAW) reported a director stock option grant on 10/12/2025. The filing shows a grant of 11,530 stock options with an exercise price of $3.01 per share. The options vest 100% on 10/12/2026 and expire on 10/12/2035.
Following the transaction, the reporting person held 11,530 derivative securities, with ownership listed as Direct. This was a routine equity award; no common shares were listed in the non-derivative table.
Traws Pharma, Inc. filed a Form 4 reporting a director stock option grant. On 10/12/2025, the reporting person received a stock option to purchase 11,530 shares of common stock at an exercise price of $3.01 per share.
The option vests 100% on 10/12/2026 and expires on 10/12/2035. Following this grant, 11,530 derivative securities were beneficially owned on a direct basis. The filing lists no transactions in non-derivative common stock.
Traws Pharma (TRAW) disclosed a Form 4 showing a director received a stock option grant. The award covers 11,530 options with an exercise price of $3.01 per share, granted on October 12, 2025.
The options vest 100% on the first anniversary of the grant date and become exercisable on October 12, 2026, with an expiration on October 12, 2035. Following the transaction, the reporting person held 11,530 derivative securities, reported as Direct (D) ownership.
Traws Pharma, Inc. (TRAW) filed a Form 4 disclosing a director stock option grant. On 10/12/2025, the reporting person acquired 11,530 stock options at a $3.01 exercise price. The options vest 100% on the first anniversary of the grant date and expire on 10/12/2035. Following the transaction, 11,530 derivative securities were beneficially owned on a direct basis.
Traws Pharma (TRAW) reported an insider equity grant. CEO and Director Iain Dukes received a stock option for 64,839 shares at an exercise price of $3.01 on 10/12/2025.
The option vests 100% on 10/12/2026 and expires on 10/12/2035. Following the grant, 64,839 derivative securities were beneficially owned, held directly. The filing reflects a routine equity compensation award.
Traws Pharma (TRAW) reported an insider equity award. The company’s Chief Medical Officer filed a Form 4 disclosing a grant of 32,406 stock options on 10/12/2025 with an exercise price of $3.01 per share. The options vest 100% on the first anniversary of the grant date (10/12/2026) and carry an expiration date of 10/12/2035. The filing lists 32,406 derivative securities beneficially owned following the transaction, held under direct ownership.
Traws Pharma (TRAW) reported an insider equity award. Chief Operating Officer and Director Nikolay Savchuk was granted a stock option for 22,435 shares at an exercise price of $3.01 on 10/12/2025.
The option vests 100% on 10/12/2026 and expires on 10/12/2035. The filing lists the holdings as Direct (D). This is a routine compensatory grant disclosed on Form 4.